Biotech company Biogen lowered its full-year profit forecast, citing higher costs related to its purchase of drug maker Reata Pharmaceuticals as well as the launch of its Alzheimer's drug.

Share:
More In Business
FTC Sues Anesthesia Partners
The Federal Trade Commission is suing one of the country's top anesthesia staffing companies for alleged anti-competitive practices.
Load More